Secondary analysis of response and remission rates in biologically naive patients: dose escalation imputed as non-response
| 6 Months | 12 Months | |||||
|---|---|---|---|---|---|---|
| INF | ADA | ETA | INF | ADA | ETA | |
| mACR response | ||||||
| No of patients | 230 | 235 | 222 | 182 | 190 | 178 |
| mACR 20 | ||||||
| Responders (%) | 25.7 | 28.9 | 37.4 | 23.6 | 25.2 | 31.5 |
| Adjusted OR | 1.00 | 0.97 (0.63–1.49) | 1.50 (1.06–2.13) | 1.00 | 1.03 (0.2–1.70) | 1.60 (0.98–1.69) |
| mACR50 | ||||||
| Responders (%) | 13.5 | 18.7 | 26.6 | 18.1 | 16.8 | 20.8 |
| Adjusted OR | 1.00 | 1.16 (0.64–2.12) | 2.04 (1.24–3.35) | 1.00 | 0.73 (0.47–1.15) | 1.10 (0.65–1.86) |
| mACR70 | ||||||
| Responders (%) | 9.1 | 9.8 | 9.9 | 11.0 | 11.6 | 11.8 |
| Adjusted OR | 1.00 | 1.04 (0.62–1.75) | 1.10 (0.58–2.09) | 1.00 | 1.03 (0.59–1.81) | 1.07 (0.62–1.85) |
| CDAI remission | ||||||
| No of patients | 254 | 249 | 242 | 199 | 202 | 189 |
| Responders (%) | 15.4 | 12.9 | 16.1 | 16.1 | 12.4 | 18.5 |
| Adjusted OR | 1.00 | 0.78 (0.37–1.62) | 1.19 (0.64–2.22) | 1.00 | 0.69 (0.43–1.10) | 1.20 (0.63–2.27) |
| DAS28 remission | ||||||
| No of patients | 103 | 107 | 116 | 71 | 75 | 72 |
| Responders (%) | 26.2 | 25.2 | 28.4 | 28.1 | 32.0 | 37.5 |
| Adjusted OR | 1.00 | 1.08 (0.74–1.58) | 1.26 (0.68–2.33) | 1.00 | 1.22 (0.64–2.35) | 1.57 (0.91–2.72) |
ADA, adalimumab; CDAI, clinical disease activity index; DAS28, disease activity score employing 28-joint count; ETA, etanercept; INF, infliximab; mACR, modified American College of Rheumatology.